DNA RNA and Cells
4 November 2022
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-1012 November 2022
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO2 November 2022
Brexogen’s Exosome Therapy for Atopic Dermatitis, ‘BRE-AD01’ Accepted for Phase 1 Clinical Trials by US FDA1 November 2022
Turnstone Biologics Announces FDA Clearance of IND for TIDAL-01, a Next-Generation TIL Therapy for Solid Tumors26 October 2022
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK21 October 2022
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial20 October 2022
Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency19 October 2022
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors18 October 2022
Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis18 October 2022
EditForce Realizes RNA-editing Technology of “U-to-C”News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports